Long-term efficacy and safety of iloperidone: an update

References

• IvlevaERTammingaCAPsychosis as a defining dimension in schizophreniaSadockBJSadockVARuizPKaplan and Sadock’s Comprehensive Textbook of Psychiatry9th edPhiladelphia, PALippincott Williams and Wilkins200915941596
   Google Scholar
• RadoJTJanicakPGSchizophreniaRakelREBopeEConn’s Current Therapy61st edPhiladelphia, PASaunders200911281131
   Google Scholar
• IchikawaJLiZDaiJMeltzerHYAtypical antipsychotic drugs, quetiapine, iloperidone, and melperidone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonismBrain Res2002956234935712445705
   PubMed Web of Science ®Google Scholar
• KalkmanHOFeuerbachLotscherESchoeffterPFunctional characterization of the novel antipsychotic iloperidone at human D2, D3, α2C, 5-HT6, and 5-HT1A receptorsLife Sci20037391151115912818723
   PubMed Web of Science ®Google Scholar
• KalkmanHOSubramanianNHoyerDExtended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disordersNeuropsychopharmacology200125690491411750183
   PubMed Web of Science ®Google Scholar
• CitromeLIloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinionExpert Opin Drug Metab Toxicol20106121551156421034370
   PubMed Web of Science ®Google Scholar
• SubramanianNKalkmanHOReceptor profile of P88-8991 and P95-12113, metabolites of the novel antipsychotic iloperidoneProg Neuropsychopharmacol Biol Psychiatry200226355356011999907
   PubMed Web of Science ®Google Scholar
• PotkinSGLitmanRETorresRWolfgangCDEfficacy of iloperidone in the treatment of schizophrenia: initial Phase III studiesJ Clin Psychopharmacol2008282 Suppl 1S4S1118334911
   PubMed Web of Science ®Google Scholar
• KaySRFiszbeinAOplerLAThe positive and negative syndrome scale (PANSS) for schizophreniaSchizophr Bull19871322612763616518
   PubMed Web of Science ®Google Scholar
• CutlerAJKalaliAHWeidenPJHamiltonJWolfgangCDFour-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophreniaJ Clin Psychopharmacol2008282 Suppl 1S20S2818334909
   PubMed Web of Science ®Google Scholar
• CutlerAJBishopJRAn update on the investigational antipsychotic iloperidone: an expert interview with Andrew J. Cutler, MDMedscape Psychiatry4162008 Available from: http://www.medscape.com/viewarticle/571878Accessed September 21, 2009
   Google Scholar
• CitromeLMengXHochfeltMStahlSEfficacy of iloperidone in the short-term treatment of schizophrenia: a post-hoc analysis of pooled patient data from four Phase III, placebo- and active-controlled trialsHum Psychpharmacol20132712432
   Web of Science ®Google Scholar
• KaneJMLaurielloJLaskaEDi MarinoMWolfgangCDLong-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophreniaJ Clin Psychopharmacol2008282 Suppl 1S29S3518334910
   PubMed Web of Science ®Google Scholar
• CutlerAJKalaliAHMattinglyGWKunovacJMengXLong-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trialCNS Spectr2013181435423312567
   PubMed Web of Science ®Google Scholar
• WeidenPJCutlerAJPolymeropoulosMHWolfgangCDSafety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trialsJ Clin Psychopharmacol2008282 Suppl 1S12S1918334908
   PubMed Web of Science ®Google Scholar
• DuttaABaruaSDanAChakrabortyKMandalMIloperidone-induced galactorreha in a middle-aged femaleIndian J Psychol Med201234439639823723555
   PubMedGoogle Scholar
• FreemanSAIloperidone-induced retrograde ejaculationInt Clin Pychopharmacol2013283156
   PubMed Web of Science ®Google Scholar
• GuanciNAggarwalRSchleiferSAtypical neuroleptic malignant syndrome associated with iloperidone administrationPsychosomatics201253660360523157999
   PubMed Web of Science ®Google Scholar
• AchaliaRAndradeCVentricular premature contractions associated with iloperidoneIndian J Psychiatry201355219519623825860
   PubMed Web of Science ®Google Scholar
• LiebermanJAStroupTSMcEvoyJPEffectiveness of antipsychotic drugs in patients with chronic schizophreniaN Engl J Med2005353121209122316172203
   PubMed Web of Science ®Google Scholar
• LavedanCLicameleLVolpiSAssociation of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association studyMol Psychiatry200914880481918521090
   PubMed Web of Science ®Google Scholar
• VolpiSPotkinSGMalhotraAKLicameleLLavedanCApplicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophreniaJ Clin Psychiatry200970680180919573479
   PubMed Web of Science ®Google Scholar
• VolpiSHeatonCMackKWhole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophreniaMol Psychiatry200914111024103118521091
   PubMed Web of Science ®Google Scholar
• FijalBAStaufferVLKinonBJAnalysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidoneJ Clin Psychiatry201273336737121813073
   PubMed Web of Science ®Google Scholar
• De HertMYuWDetrauxJSweersKvan WinkelRCorrellCUBody weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysisCNS Drugs201226973375922900950
   PubMed Web of Science ®Google Scholar
• BoboWVAsenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adultsExpert Rev Clin Pharmacol201361619123272794
   PubMed Web of Science ®Google Scholar